MIT engineers trained a language model on yeast codon usage to design genes that boost protein production, outperforming commercial tools for five of six proteins. The approach could lower drug development costs by improving yields of protein-based medicines.
The European Medicines Agency is enforcing clinical trial transparency and has launched a new vaccine information initiative, while a coalition of health professionals warns of suboptimal vaccination coverage across Europe. An analysis also shows that only a portion of EMA-approved medicines are available to NHS patients in England after additional assessments.
Two research teams have developed catalytic methods for synthesizing chiral sulfur compounds with antiviral potential. One approach uses an organocatalytic strategy to create vinyl sulfinamides that bind to SARS-CoV-2 and HIV-1 proteins, while another employs copper catalysis for high-yield production of chiral sulfilimines. Both methods address critical gaps in accessing valuable chemical space for drug discovery.
Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for Moderna's mCOMBRIAX, the world's first combination Covid-19 and influenza vaccine, for individuals 50 years and older.
Anbio Biotechnology shares gained following an upgrade from a sell rating to hold. The company reported $0.04 earnings per share and $2.29 million in quarterly revenue.
Moderna announced UK authorization for its updated Spikevax vaccine targeting the LP.8.1 variant and European Commission marketing authorization for mNEXSPIKE, its third vaccine approved in the EU.
A Lancet study of 1.1 million people found that 65% of those initially hesitant about COVID-19 vaccines went on to get vaccinated, with concerns about mRNA technology and safety declining as evidence accumulated during the rollout.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07743580 |
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07720596 |
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era |
COMPLETED | |
| NCT07387211 |
Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region |
COMPLETED | NA |
| NCT07266558 |
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06864143 |
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age |
COMPLETED | PHASE2 |
| NCT06743334 |
Secondary Databased Post-marketing Surveillance Study of BNT162b2 |
COMPLETED | |
| NCT06689423 |
Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay |
COMPLETED | |
| NCT06684379 |
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) |
RECRUITING | PHASE1/PHASE2 |
| NCT06610643 |
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients |
NOT_YET_RECRUITING | NA |
| NCT06585241 |
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations |
RECRUITING | PHASE4 |
